Echosens and Boehringer Ingelheim Expand Partnership for MASH Diagnosis
Echosens and Boehringer Ingelheim have announced an expansion of their long-standing partnership to advance the diagnosis and care of metabolic dysfunction-associated steatohepatitis (MASH), announced in a press release. This collaboration aims to address the urgent need for early screening and diagnosis of MASH, a chronic liver disease affecting over 250 million people worldwide.
The partnership will focus on raising awareness among patients, healthcare professionals, and policymakers about the importance of early detection. It will also promote the adoption of streamlined care pathways and expand access to non-invasive technologies (NITs) for MASH diagnosis. Echosens' FibroScan®, a non-invasive liver assessment technology, will continue to play a crucial role in Boehringer Ingelheim's ongoing research and clinical trials.
By combining their diagnostic and therapeutic expertise, the two companies aim to close gaps in awareness and clinical adoption, ultimately improving liver health outcomes globally.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Life Sciences
Oct 22 BioStack Raises $9.5 Million for Medical AI Data Network Oct 22 Warp Sciences Raises $215 Million to Automate Drug Discovery Labs Oct 22 FDA Clears RIVANNA BoneEnhance Software for Accuro XV Oct 22 Tufts Medicine Uses Humata Health to Automate Prior Authorization Oct 22 HHS Plans Sole Source Claude Contract With AnthropicLife AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Whitepaper
Tensordyne Napier: What If One Rack Could Do the Work of Nine?
Tensordyne
This Tensordyne whitepaper presents Napier, an inference-focused AI processor and rack-scale system based on the company’s TDN Math logarithmic number system. It examines infrastructure requirements for large mixture-of-experts and agentic models, compares major inference architecture approaches, and details the TDN AIP processor, TDN72 pod, TDN Link fabric, and Napier Ultra configuration. The paper reports simulation-based performance, cost, and accuracy-validation results, including Tensordyne’s projected comparison of one Napier rack with a nine-rack Nvidia Rubin plus Groq deployment; the chip is reported as taped out and in fabrication.
Read moreYou may also like
Brainomix and Pulmonary Fibrosis Foundation Partner on AI Lung Imaging Research
Helio Genomics Presents Four HelioLiver Studies on Liver Cancer Detection
Helfie AI and Health Innovation South West to Test Smartphone Hypertension Screening
AIRS Medical Gets FDA Clearance for MRI Body Composition Tool
AstraZeneca and Oracle Partner on AI for Clinical Trials
Daily AI Brief: the AI news that matters, in your inbox.